The Promise of Blood-Based Biomarkers in Early Detection and Care of Alzheimer’s Disease

Abstract

BBMs play a crucial role in combating Alzheimer’s disease and should be prioritized. To embed them in routine primary care, it is essential for governments and health organizations to finance evaluations in varied demographics, establish coverage policies, and integrate BBMs into existing workflows. Their accuracy, comparable to traditional invasive methods, enables early detection of AD, allowing for lifestyle adjustments and therapies that may hinder or delay disease progression. For patients, this means gaining a sense of control, meeting their needs, and moving forward without the burden of an uncertain diagnosis. This is not merely a transient trend; embracing BBMs could fundamentally alter the perception of aging in a future where Alzheimer’s disease diminishes in prominence.